enGene Holdings Inc. (ENGNW)

NASDAQ: ENGNW · Real-Time Price · USD · Warrants
0.7579
+0.0579 (8.27%)
Sep 29, 2025, 4:00 PM EDT - Market closed
8.27%
Market Cap330.19M
Revenue (ttm)n/a
Net Income (ttm)-94.72M
Shares Out 51.19M
EPS (ttm)-1.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,223
Open0.7500
Previous Close0.7000
Day's Range0.7300 - 0.7579
52-Week Range0.5100 - 2.7400
Beta-0.39
Analystsn/a
Price Targetn/a
Earnings Daten/a

About ENGNW

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Ronald H. Cooper
Employees 57
Stock Exchange NASDAQ
Ticker Symbol ENGNW
Full Company Profile

News

There is no news available yet.